{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+-+Group+1%2F2+Placebo", "query": { "intervention": "Cohort 1 - Group 1/2 Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 189, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+-+Group+1%2F2+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T02:03:35.255Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02190747", "title": "An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Palovarotene", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clementia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 40, "start_date": "2014-07-14", "completion_date": "2016-05-23", "has_results": true, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 2, "location_summary": "San Francisco, California • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02190747" }, { "nct_id": "NCT03840057", "title": "Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro Intestinal Bleeding", "Upper Gastrointestinal Bleeding" ], "interventions": [ { "name": "Azithromycin Injection", "type": "DRUG" }, { "name": "Metoclopramide Injectable Solution", "type": "DRUG" }, { "name": "Sodium chloride 0.9%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Waihong Chung", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 435, "start_date": "2020-07-01", "completion_date": "2021-07", "has_results": false, "last_update_posted_date": "2020-08-07", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840057" }, { "nct_id": "NCT05048875", "title": "An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dengue" ], "interventions": [ { "name": "Cohort 1 - Group 1 JNJ High Dose", "type": "DRUG" }, { "name": "Cohort 1 - Group 2 JNJ Medium Dose", "type": "DRUG" }, { "name": "Cohort 1 - Group 2 JNJ Low Dose", "type": "DRUG" }, { "name": "Cohort 1 - Group 1/2 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 56, "start_date": "2022-02-03", "completion_date": "2024-09-10", "has_results": true, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Burlington, Vermont", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT05048875" }, { "nct_id": "NCT03140527", "title": "Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "Cystic Fibrosis" ], "interventions": [ { "name": "PTI-801", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PTI-808", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Proteostasis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2017-04-10", "completion_date": "2020-02-27", "has_results": false, "last_update_posted_date": "2020-04-30", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Altamonte Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03140527" }, { "nct_id": "NCT04228783", "title": "A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ebola" ], "interventions": [ { "name": "Ad26.ZEBOV", "type": "BIOLOGICAL" }, { "name": "MVA-BN-Filo", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 974, "start_date": "2020-02-18", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 7, "location_summary": "Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04228783" }, { "nct_id": "NCT01220128", "title": "Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Aromatase inhibitor", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Carboplatin AUC", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2011-04-11", "completion_date": "2014-11-14", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 8, "location_summary": "Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Plantation", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Bend", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01220128" }, { "nct_id": "NCT02542605", "title": "To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PACAP-38 Challenge Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 35, "start_date": "2015-11-11", "completion_date": "2017-11-08", "has_results": true, "last_update_posted_date": "2019-06-03", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542605" }, { "nct_id": "NCT03077477", "title": "Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Medication Toxicity", "Tolerance" ], "interventions": [ { "name": "AMXT 1501", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 0, "start_date": "2018-06-12", "completion_date": "2018-06-12", "has_results": false, "last_update_posted_date": "2018-06-14", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03077477" }, { "nct_id": "NCT07525544", "title": "A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4770359", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 214, "start_date": "2026-05-14", "completion_date": "2027-05-05", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07525544" }, { "nct_id": "NCT05585606", "title": "Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Ischemic Stroke (AIS)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "scp776 (1.9 mg/kg)", "type": "DRUG" }, { "name": "scp776 (3.8 mg/kg)", "type": "DRUG" }, { "name": "scp776 (4.8 mg/kg)", "type": "DRUG" }, { "name": "scp776 (all dose levels)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silver Creek Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2022-10-19", "completion_date": "2025-09-15", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-02T02:03:35.255Z", "location_count": 22, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585606" } ] }